Hiring in life sciences? Share your open positions with our professional community. Read more Close

Advertisement

The methionine cycle sustains the mesenchymal phenotype of tumor cells and drives PDA progression

Created on 08 Nov 2026

Authors

Vasseur, S., Guillaumond, F., Elodie, M., Da-Costa, Q., Finetti, P., Bertucci, F., Tomasini, R., Dusetti, N. J., Mamessier, E., Efthymiou, G., Jaune-Pons, E., Gouirand, V., Tubiana, S. S., Neuzillet, C., Lohmann, E., Djefaflia-Beloribi, S., Grenot, P.

Abstract

Mesenchymal traits are associated with poor prognosis in Pancreatic Ductal Adenocarcinoma (PDA), but direct targeting of mesenchymal tumor cells remains a challenge. Metabolic profiling of tumor cells isolated from murine PDA and liver metastases (LM) revealed that LM rely more on the methionine cycle than does primary PDA. This metabolic shift was specifically associated with increased activation of the methionine cycle in mesenchymal tumor cells compared to differentiated tumor cells. We show that the targeting of the key enzyme of the methionine cycle S-adenosylhomocysteine hydrolase (SAHH) in mesenchymal cells lowers the levels of homocysteine (Hcy) and glutathione, resulting in reduced antioxidant capacity, deregulated intracellular calcium homeostasis, and ultimately loss of mesenchymal markers. Together, these events decrease cell proliferation and invasion, blunting the tumorigenic and metastatic potential of SAHH-deficient cells, eventually impeding tumor growth and progression of the metastatic disease. Clinically, the high expression of SAHH in patients with mesenchymal PDA is correlated with poor survival, positioning SAHH as a potential therapeutic target to impede the pro-metastatic, mesenchymal phenotype of PDA.

Preprint server: bioRxiv
The authors list and abstract were imported from bioRxiv on 08 Nov 2026.

Advertisement

Stats

  • Community rating n/a 0 votes
  • Your rating

1-terrible, 9-excellent. How would you rate this preprint? Sign in in to submit your rating.

  • Recommendations n/a n/a positive of 0 vote(s)
  • Views 17
  • Comments 0

Recommended by

  • No recommendations yet.

Post a comment

You need to be signed in to post comments. You can sign in here.

Comments

There are no comments yet.

Advertisement